Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001017307 | SCV001178372 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-02-12 | criteria provided, single submitter | clinical testing | The c.1101-83_1106del89 alteration, spans intron 9 through coding exon 10 of the TP53 gene, results from a deletion of 89 nucleotides at positions c.1101-83 to c.1106, causing a deletion of the native splice acceptor site. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay however, this deletion occurs at the 3' terminus of TP53 , is not expected to trigger nonsense-mediated mRNA decay, and impacts only the last exon of the protein. The exact functional impact of the deleted exon is unknown at this time. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |